Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can...
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints....
CNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like....
HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed s...
Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare ...
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are ...
Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascula...
Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra....
CNBC's Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma....
Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyop...
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints....